Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Connor A et al. | Generic tacrolimus in renal transplantation: trough blood concentration as a surrogate for drug exposure. | 2012 | Transplantation | pmid:23318306 |
Plock JA et al. | Adipose- and Bone Marrow-Derived Mesenchymal Stem Cells Prolong Graft Survival in Vascularized Composite Allotransplantation. | 2015 | Transplantation | pmid:26102613 |
Gurk-Turner C et al. | Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients. | 2008 | Transplantation | pmid:18497682 |
Haririan A et al. | Polyomavirus reactivation in native kidneys of pancreas alone allograft recipients. | 2003 | Transplantation | pmid:12717201 |
Arns W et al. | Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial. | 2017 | Transplantation | pmid:28658202 |
Taber DJ et al. | Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation. | 2017 | Transplantation | pmid:28658199 |
Diémé B et al. | Assessing the metabolic effects of calcineurin inhibitors in renal transplant recipients by urine metabolic profiling. | 2014 | Transplantation | pmid:24598938 |
Han DH et al. | Effect of sirolimus on calcineurin inhibitor-induced nephrotoxicity using renal expression of KLOTHO, an antiaging gene. | 2010 | Transplantation | pmid:20562737 |
Budde K et al. | Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. | 2007 | Transplantation | pmid:17318074 |
Stegall MD et al. | Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine. | 1997 | Transplantation | pmid:9422404 |
Shibutani S et al. | Effects of immunosuppressants on induction of regulatory cells after intratracheal delivery of alloantigen. | 2005 | Transplantation | pmid:15849542 |
Tory R et al. | Tacrolimus-induced elevation in plasma triglyceride concentrations after administration to renal transplant patients is partially due to a decrease in lipoprotein lipase activity and plasma concentrations. | 2009 | Transplantation | pmid:19584682 |
Weiler N et al. | Early steroid-free immunosuppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blinded trial. | 2010 | Transplantation | pmid:21048536 |
Chisholm MA et al. | Renal transplant patient compliance with free immunosuppressive medications. | 2000 | Transplantation | pmid:11063348 |
Busuttil RW et al. | General guidelines for the use of tacrolimus in adult liver transplant patients. | 1996 | Transplantation | pmid:8607197 |
Atkison PR et al. | Arteritis and increased intracellular calcium as a possible mechanism for tacrolimus-related cardiac toxicity in a pediatric transplant recipient. | 1997 | Transplantation | pmid:9311719 |
Hoogduijn MJ et al. | Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycin. | 2008 | Transplantation | pmid:19005411 |
Tzakis AG et al. | Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. | 2004 | Transplantation | pmid:15114087 |
Talbot D et al. | Alopecia as a consequence of tacrolimus therapy in renal transplantation? | 1997 | Transplantation | pmid:9415574 |
Gregory CR et al. | Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. | 1995 | Transplantation | pmid:7533955 |
Gill JS et al. | Screening for de novo anti-human leukocyte antigen antibodies in nonsensitized kidney transplant recipients does not predict acute rejection. | 2010 | Transplantation | pmid:20098280 |
Zhao W et al. | Pharmacokinetic interaction between tacrolimus and amlodipine in a renal transplant child. | 2012 | Transplantation | pmid:22450597 |
Pascual J et al. | Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation. | 2009 | Transplantation | pmid:19136902 |
Ciancio G et al. | A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. | 2005 | Transplantation | pmid:16123718 |
Vossen M et al. | Bone quality in swine composite tissue allografts: effects of combination immunotherapy. | 2005 | Transplantation | pmid:16123723 |
Suzuki S et al. | Neutrophil infiltration as an important factor in liver ischemia and reperfusion injury. Modulating effects of FK506 and cyclosporine. | 1993 | Transplantation | pmid:7685932 |
Lauria MW et al. | Metabolic long-term follow-up of functioning simultaneous pancreas-kidney transplantation versus pancreas transplantation alone: insights and limitations. | 2010 | Transplantation | pmid:20061923 |
Pascual M et al. | Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. | 1998 | Transplantation | pmid:9869086 |
Strumph P et al. | The effect of FK506 on glycemic response as assessed by the hyperglycemic clamp technique. | 1995 | Transplantation | pmid:7542815 |
Baran DA et al. | Tacrolimus in cardiac transplantation: efficacy and safety of a novel dosing protocol. | 2002 | Transplantation | pmid:12438960 |
Higgins R et al. | Rises and falls in donor-specific and third-party HLA antibody levels after antibody incompatible transplantation. | 2009 | Transplantation | pmid:19300192 |
Steiner RW | Steroid withdrawal in kidney transplantation: the subgroup fallacy. | 2011 | Transplantation | pmid:21336084 |
Arai K et al. | Limb allografts in rats immunosuppressed with FK506. I. Reversal of rejection and indefinite survival. | 1989 | Transplantation | pmid:2479130 |
Vathsala A et al. | The immunosuppressive antagonism of low doses of FK506 and cyclosporine. | 1991 | Transplantation | pmid:1713361 |
Kawano K et al. | A protective effect of FK506 in ischemically injured rat livers. | 1991 | Transplantation | pmid:1713362 |
Yuzawa K and Fukao K | Topical FK506 ointment for skin grafting. | 1998 | Transplantation | pmid:9565111 |
Higgins RM et al. | Conversion from tacrolimus to cyclosporin in stable renal transplant patients: safety, metabolic changes, and pharmacokinetic comparison. | 2000 | Transplantation | pmid:10919600 |
Zieliński A et al. | Simultaneous pancreas-kidney transplant from living related donor: a single-center experience. | 2003 | Transplantation | pmid:12923442 |
Markus PM et al. | Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. | 1991 | Transplantation | pmid:1718063 |
Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Drug levels in PHAs who receive liver transplants. | 2003 Apr-May | TreatmentUpdate | pmid:17216847 | |
Kunz J and Hall MN | Cyclosporin A, FK506 and rapamycin: more than just immunosuppression. | 1993 | Trends Biochem. Sci. | pmid:7694398 |
Cardenas ME et al. | Signal-transduction cascades as targets for therapeutic intervention by natural products. | 1998 | Trends Biotechnol. | pmid:9807840 |
Snyder SH et al. | Neural actions of immunophilin ligands. | 1998 | Trends Pharmacol. Sci. | pmid:9509898 |
Liu J | FK506 and ciclosporin: molecular probes for studying intracellular signal transduction. | 1993 | Trends Pharmacol. Sci. | pmid:7692652 |
Chang JY et al. | FK506 and rapamycin: novel pharmacological probes of the immune response. | 1991 | Trends Pharmacol. Sci. | pmid:1710854 |
Sommerer C et al. | Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial. | 2016 | Trials | pmid:26888217 |
Nashan B et al. | Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial. | 2015 | Trials | pmid:25873064 |
Bajetta E et al. | Merkel cell carcinoma after liver transplantation: a case report. | 2007 May-Jun | Tumori | pmid:17679476 |
Vennarecci G et al. | [Acute liver toxicity of antiretroviral therapy (HAART) after liver transplantation in a patient with HIV-HCV coinfection and associated hepatocarcinoma (HCC)]. | 2003 Jul-Aug | Tumori | pmid:12903579 |
Dinçkan A et al. | Evaluation of the first 100 liver transplantations. | 2008 | Turk J Gastroenterol | pmid:18386237 |